

## Translation

Notice: This document is a translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.



August 20, 2025

Company name: Taiko Pharmaceutical Co., Ltd.  
Name of representative: Takashi Shibata, President and CEO  
(Securities code: 4574; Tokyo Stock Exchange Prime)  
Inquiries: Toru Nakajo, V P, Accounting Department, Corporate Division  
(Email: ir@seirogan.co.jp)

## Notice regarding the completion of liquidation of an overseas consolidated subsidiary (recording of extraordinary profit) and revision of consolidated earnings forecasts

Taiko Pharmaceuticals Co., Ltd. (hereinafter referred to as "the Company") has been proceeding with the liquidation procedures of its consolidated subsidiary, Taiko Environmental Technologies(Shanghai) Co., Ltd. (hereinafter referred to as "Shanghai Taiko"). We hereby announce that we have confirmed the completion of Shanghai Taiko 's liquidation as of August 11, 2025.

Shanghai Taiko has resolved to liquidate at its general shareholders' meeting to be held on December 20, 2024.

In addition, as a result of the completion of the liquidation, we expect to record a special gain in the consolidated financial results for the fiscal year ending December 2025. Accordingly, we have decided to revise the consolidated earnings forecast for the fiscal year ending December 2025, which was previously announced on February 13, 2025.

### 1. Completion of Liquidation of Overseas Consolidated Subsidiary and Recognition of Special Gain

- ( 1 ) Date of Completion of Liquidation  
August 11, 2025

#### ( 2 ) Overview of the Liquidated Subsidiary

Name	Taiko Environmental Technologies (Shanghai) Co., Ltd.
Location	Room115. NO328. HuaShan Road. Shanghai. China
Job title and name of representative	Chairman Joh Shibata
Business Description	The Infection Control Business Sell our products
Share capital	1 million US dollars
Major shareholders and ownership ratios	Our company: 100%

#### ( 2 ) Recognition of Special Gain

As a result of the completion of this liquidation, Shanghai Taiko will be excluded from the scope of consolidation. Consequently, a foreign currency translation adjustment gain of 142million yen, arising from the reversal of the foreign currency translation adjustment account recorded in the Company's consolidated balance sheet, is expected to be recognized as a special gain in the fiscal year ending December 2025.

## 2. Revision of the consolidated business results forecast

### (1) Revision of the consolidated business results forecast for the fiscal year ending December 31, 2025 (from January 1, 2025 to December 31, 2025)

(Millions of yen)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Basic earnings per share
Previous forecast (A) (announced on February 13, 2025)	6,300	215	200	300	5.98yen
Revised forecast (B)	6,300	215	200	450	8.96yen
Amount changed (B-A)	0	0	0	150	
Percentage of change (%)	0	0	0	50.0	
(Reference) Actual results for the fiscal year ended December 31, 2024	6,292	629	688	898	17.90

### (2) Reason for the Revision

Due to the recognition of the aforementioned special gain, net income attributable to owners of the parent is expected to exceed the previously announced forecast. Accordingly, we will revise the consolidated earnings forecast for the fiscal year ending December 2025, which was announced on February 13, 2025.

The above forecast is based on information currently available to the Company and certain assumptions that are deemed reasonable. Actual results may differ due to various factors.

END